At the heart of the Oncopole of Toulouse, the CRCT, together with all its partners (institutional, academic, clinical, industrial, charities…), stimulates innovation in terms of research and teaching in the fight against cancer.
The CRCT is a joint Research Unit Inserm & University Toulouse III Paul Sabatier
3 research teams are also labelled by the CNRS
Researchers, clinicians and supports
PhD students and post-doctoral fellows
Targeted therapies against cancer cells – How to overcome adaptive response defence mechanisms of cancer cells ?
What signals do cancer cells send to prevent these therapies from working? A targeted therapy is a therapy that prevents a specifically active signal in tumour cells. Our team is interested in inhibitors of PI3Ks, innovative targeted therapies for solid and liquid...
The radiation dose delivered to the patient in radiotherapy is usually calculated using commercial software ("TPS") which allows a very accurate calculation in the vast majority of clinical cases. However, it is sometimes necessary to have access to a reference...
Overexpression of the oncogenic long noncoding RNA LONA in acute myeloid leukemia and change in its cellular location by the mutant protein NPM1c+.
In this study, we describe the oncogenic role of a novel long noncoding RNA (lncRNA) called LONA (LncRNA Overexpressed in NPM1 mutated Acute myeloid leukemia) overexpressed in patients with acute myeloid leukemia (AML) carrying the mutation of the nucleophosmin NPM1....
Centre de Recherches en Cancérologie de Toulouse
2 avenue Hubert Curien
31037 TOULOUSE CEDEX 1 – FRANCE